Eckert & Ziegler will be admitted to SDax
Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in isotope-related applications in medicine, science and industry will be admitted to SDax as of 24 June 2019. This decision was announced by the Working Committee for Equity Indices at Deutsche Börse AG, Frankfurt / Main, after yesterday’s regular review of the small-cap index. In addition to the high transparency requirements of the Prime Standard, the Eckert & Ziegler shares thereby also fulfill the relevant index size criteria of market capitalization and liquidity.
“We are very delighted to be admitted to SDAX. It is a further confirmation of the successful development of our company in the recent years and the attractiveness of our share. In the future, Eckert & Ziegler will thus gain even more attention. I would like to thank all our employees for this great success”, explained Dr. Andreas Eckert, CEO of Eckert & Ziegler AG."
The SDax comprises 70 companies which rank below the companies in the MDax and fulfill the selection criteria defined by Deutsche Börse. These companies must be listed in the Prime Standard segment and must have a minimum free float of ten percent. The stocks that fulfill these requirements are selected for the index on the basis of two size criteria, market capitalization based on free float and trading volume.
About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with around 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine.
Contributing to saving lives.
source: Eckert & Ziegler AG
Change in the Board of Directors of the Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association
OMEICOS Therapeutics Announces First-Dosing in Phase 2 Clinical Study Evaluating its Lead Program OMT-28 in Patients with Persistent Atrial Fibrillation
Glycotope Expands Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies to Include Marketed Anti-Tumor Antibodies
Here you can search in all press releases from 2010 on: